|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on this information, in this study we aimed to evaluate the relationship between serum ANGPTL-4 levels and obesity and hepatosteatosis in adolescents.
|
31419758 |
2020 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phillyrin lowers body weight in obese mice via the modulation of PPAR<beta>/<delta>-ANGPTL 4 pathway.
|
28320596 |
2019 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the cross-sectional study, circulating ANGPTL-4 levels were lower in children with obesity than in those with normal weight.
|
31207920 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4.
|
30518876 |
2019 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aim to investigate the regulation of circulating ANGPTL-4 levels in obesity, T2D, and after changes in body weight.
|
29536615 |
2018 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate ANGPTL4 plasma levels and PPARγ gene expression in peripheral blood mononuclear cells (PBMCs) of children and adolescents with obesity and their association with metabolic parameters.
|
28733963 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to better characterise the role of ANGPTL4 in glucose homeostasis and metabolic dysfunction during obesity.
|
29502266 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiopoietin-like protein 4 (ANGPTL4) is related to gestational weight gain in pregnant women with obesity.
|
30127377 |
2018 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most notably, ALA supplementation reduced Angptl4 gene expression compared with obese control and obese-LA supplemented rats and reduced circulating ANGPTL4 serum concentrations.
|
29727591 |
2018 |
|
Obesity
|
0.400 |
Therapeutic
|
disease |
CTD_human |
We show here that the purified FLD of Angptl4 is sufficient to stimulate lipolysis in mouse primary adipocytes and that increasing circulating FLD levels in mice through adenovirus-mediated overexpression (Ad-FLD) not only induces WAT lipolysis <i>in vivo</i> but also reduces diet-induced obesity without affecting LPL activity.
|
28842503 |
2017 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to investigate the association of ANGPTL4 variants (E40K and T266M) with triglyceride levels and with cardiovascular risk factors, such as metabolic syndrome (MetS) and obesity in type 2 diabetic Tunisian population.
|
27004807 |
2016 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
With an eye on an effective strategy to improve health using ANGPTL4, we will focus on: health issues associated with ANGPTL4 expression, including obesity, Type 2 diabetes, cardiovascular diseases and cancer; several modulators of ANGPTL4 of chemical, microbiological, food and host origin; and the correlation of the specific ANGPTL4 isoforms with these modulators and their health effects.
|
22462789 |
2012 |
|
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to determine whether ANGPTL4 E40K and T266M are associated with triglyceride levels in the setting of obesity and T2D, and whether modification of triglyceride levels by these genetic variants is altered by a lifestyle intervention designed to treat T2D.
|
21714923 |
2011 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that variation in Angptl4 concentration was only modestly accounted for by genetic factors and suggest a role for Angptl4 in acquired obesity in humans.
|
21596930 |
2011 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.
|
18728224 |
2008 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the expression of candidate genes involved in adipocyte proliferation and/or differentiation [CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPdelta, GATA domain-binding protein 3 (GATA3), C/EBPbeta, peroxisome proliferator-activated receptor (PPAR) gamma2, signal transducer and activator of transcription 5A (STAT5A), Wnt-10b, tumor necrosis factor alpha, sterol regulatory element-binding protein 1c (SREBP1c), 11 beta-hydroxysteroid dehydrogenase, PPARG angiopoietin-related protein (PGAR), insulin-like growth factor 1, PPARgamma coactivator 1alpha, PPARgamma coactivator 1beta, and PPARdelta] in subcutaneous adipose tissue from 42 obese individuals with type 2 diabetes and 25 non-diabetic subjects matched for age and obesity.
|
17030965 |
2006 |